ANIK
Anika Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 Anika Therapeutics reported flat Q4 revenue of $30.6M but full-year…
- Apr 3 Activist stake: Anika Reports Inducement Grants Under Nasdaq Listing Rule…
- Apr 29 Anika Therapeutics reported Q1 2026 revenue of $29.6M, up 13% YoY an…
- Apr 30 to May 1 ▲ 2 days of insider buys: $223.2K by 2 insiders, avg $12.98
- Jul 29 ▲ Anika Therapeutics reported a transformative Q2 2026 beat, with GAAP…
- Aug 3 to Aug 4 ▲ 2 days of insider buys: $41.1K by 1 insider, avg $20.53
- Nov 6 Anika Therapeutics reported Q3 2026 revenue of $30.6M (+10% YoY), sl…
- Nov 6 ▼ Earnings: ANIK Q3 2026 Earnings: EPS $-0.02 (-132.7% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
3 insiders bought $264.3K at an average $13.76. No open-market sales. Price is 6% below their cost.
- InstitutionsMIXED
Q3 2026: 11 added (0 new), 12 trimmed or exited.
- AnalystsBULLISH
7 of 8 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −11.5% to 323.5K shares. 3.1 days to cover, ≈2.4% of shares.
- TrendDOWNTREND
34% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $8.2M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $5.0M |
| UBS Group AG | TRIM | $1.7M |
| Assenagon Asset Management S.A. | TRIM | $793.8K |
| MARSHALL WACE, LLP | ADD | $613.3K |
| STRS OHIO | ADD | $583.9K |
| AMERICAN CENTURY COMPANIES INC | TRIM | $579.4K |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | $253.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
8 analystsPrice is below the lowest target. Median implies +55%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only REITERATE | |
| Jul 30, 2026 | B. Riley Securities MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Fischetti Gary P Director Aug 4, 2026 | BUY | $20.3K |
Fischetti Gary P Director Aug 3, 2026 | BUY | $20.7K |
Capper Joseph H Director Jun 18, 2026 | AWARD | 10,402 sh |
HENNEMAN JOHN B III Director Jun 18, 2026 | AWARD | 10,402 sh |
CONLEY SHERYL L Director Jun 18, 2026 | AWARD | 10,402 sh |
Richard Stephen Director Jun 18, 2026 | AWARD | 10,402 sh |
Fischetti Gary P Director Jun 18, 2026 | AWARD | 10,402 sh |
HENNEMAN JOHN B III Director May 1, 2026 | BUY | $73.3K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 1 bullish · 1 bearish · 4 mixed · 7 neutral- MIXED 8-KNov 6, 2026
Anika Therapeutics reported Q3 2026 revenue of $30.6M (+10% YoY), slightly above the $29.4M…
The Hyalofast PMA rejection is a material pipeline setback that may weigh on the stock despite solid operational results and raised guidance. Watch for management's next steps on Hyalofast…
- NEUTRAL PRESS-RELEASEOct 22, 2026
Anika Therapeutics Inc. announced it will report its Q3 2026 results on November 6, 2026.
- BULLISH 8-KJul 29, 2026
Anika Therapeutics reported a transformative Q2 2026 beat, with GAAP EPS of $0.24 (vs $0.03…
The magnitude of the beat and guidance raise is significant for a $202M market cap stock. The removal of Hyalofast from 2027 guidance introduces a binary catalyst risk (FDA PMA decision) that could…
- NEUTRAL 8-KJul 14, 2026
Anika Therapeutics entered into a Fifth Amendment to its existing credit agreement with Bank of…
The extended credit facility removes near-term refinancing risk and provides committed liquidity through 2031. Monitor upcoming quarterly filings for leverage ratio and covenant compliance, as the…
All ANIK filing & press-release reports (13)
- 8-K reportNov 6, 2026
- PRESS-RELEASE reportOct 22, 2026
- 8-K reportJul 29, 2026
- 8-K reportJul 14, 2026
- 8-K reportJun 23, 2026
- INST-CLUSTER reportJun 11, 2026
- DEFA14A reportJun 8, 2026
- DEFA14A reportJun 1, 2026
- CLUSTER reportApr 30, 2026
- 8-K reportApr 29, 2026
- DEFA14A reportApr 28, 2026
- PRESS-RELEASE reportApr 15, 2026
- 8-K reportFeb 26, 2026